摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H-苯并咪唑-5-羧酸酰胺 | 116568-17-3

中文名称
1H-苯并咪唑-5-羧酸酰胺
中文别名
1H-苯并[D]咪唑-6-甲酰胺
英文名称
benzimidazole-5-carboxamide
英文别名
1H-benzo[d]imidazole-5-carboxamide;1(3)H-benzimidazole-5-carboxylic acid amide;1(3)H-Benzimidazol-5-carbonsaeure-amid;1H-benzoimidazol-5-carboxylic acid amide;1H-benzimidazole-5-carboxamide;1H-Benzo[d]imidazole-6-carboxamide;3H-benzimidazole-5-carboxamide
1H-苯并咪唑-5-羧酸酰胺化学式
CAS
116568-17-3
化学式
C8H7N3O
mdl
MFCD07506162
分子量
161.163
InChiKey
FNLQDVXHDNFXIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    584.7±23.0 °C(Predicted)
  • 密度:
    1.416±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    71.8
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:745c978d426a23f27a6c2e36c947f4e2
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1H-苯并咪唑-5-羧酸酰胺一水合肼 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以0.75 g的产率得到benzimidazol-5-carboxamidrazone
    参考文献:
    名称:
    Structure–Activity Relationships of Benzimidazole-Based Glutaminyl Cyclase Inhibitors Featuring a Heteroaryl Scaffold
    摘要:
    Glutaminyl cyclase (hQC) has emerged as a new potential target for the treatment of Alzheimer's disease (AD). The inhibition of hQC prevents of the formation of the A beta(3(pE)-40,42) species which were shown to be of elevated neurotoidcity and are likely to act as a seeding core, leading to an accelerated formation of A beta-oligomers and fibrils. This work presents a new class of inhibitors of hQC, resulting from a pharmacophore-based screen. Hit molecules were identified, containing benzimidazole as the metal binding group connected to 1,3,4-oxadiazole as the central scaffold. The subsequent optimization resulted in benzimidazoly1-1,3,4-thiadiazoles and -1,2,3-triazoles with an inhibitory potency in the nanomolar range. Further investigation into the potential binding mode of the new compound classes combined molecular docking and site directed mutagenesis studies.
    DOI:
    10.1021/jm4001709
  • 作为产物:
    参考文献:
    名称:
    Studies on the Antitubercular Compounds. XIII. Preparation of Some Derivatives of Benzimidazole and 2,1,3-Benzothiadiazole
    摘要:
    DOI:
    10.1246/bcsj.31.252
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS<br/>[FR] IMIDAZOLYL-IMIDAZOLES EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXO GROUP LTD
    公开号:WO2011123609A1
    公开(公告)日:2011-10-06
    Disclosed are compounds having the formula: wherein R1A, R1B, R2 and R3 are as defined herein, and methods of making and using the same.
    揭示了具有以下公式的化合物:其中R1A、R1B、R2和R3如本文所定义,并且制备和使用这些化合物的方法。
  • [EN] HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DE PROTÉINE
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2017175147A1
    公开(公告)日:2017-10-12
    Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    揭示了具有化学式(I-N)的化合物,其中q、r、s、A、B、C、RA1、RA2、RB1、RB2、RC1、RC2、R3、R4、R5、R6、R14、R15、R16和R17如本文所定义,或其互变异构体,或其盐,特别是其药用可接受盐。
  • [EN] BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'INHIBITEURS D'ITK
    申请人:PRINCIPIA BIOPHARMA INC
    公开号:WO2014036016A1
    公开(公告)日:2014-03-06
    The present disclosure is directed to certain inhibitors of kinases such as ITK, BLK, BMX, BTK, JAK3, TEC, TXK, HER2 (ERBB2), or HER4 (ERBB4), in particular ITK, pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.
    本公开涉及特定激酶抑制剂,如ITK、BLK、BMX、BTK、JAK3、TEC、TXK、HER2(ERBB2)或HER4(ERBB4),特别是ITK,包括这些化合物的药物组合物,以及治疗由这些激酶介导的疾病的方法。
  • [EN] DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDE ET DE TRIPEPTIDE ÉPOXY CÉTONE PROTÉASES
    申请人:ONYX THERAPEUTICS INC
    公开号:WO2014152127A1
    公开(公告)日:2014-09-25
    Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
    本文提供了二肽和三肽环氧酮蛋白酶抑制剂,其制备方法,相关的药物组合物,以及使用它们的方法。例如,本文提供了化合物的化学式(X):及其药用盐和包括这些化合物的组合物。本文提供的化合物和组合物可以用于治疗增生性疾病,包括癌症和自身免疫疾病。
  • [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE
    申请人:KANCERA AB
    公开号:WO2017108282A1
    公开(公告)日:2017-06-29
    A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
    化合物的化学式(Ia)或(Ib)或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶抑制剂,因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。
查看更多